WHEN IT’S
HARD BELLY
(EXCESS VISCERAL
ABDOMINAL FAT)
IT MAY BE TIME FOR
EGRIFTA SVTM
IF YOU ARE LIVING WITH
HIV AND LIPODYSTROPHY
ASK YOUR HEALTHCARE PROVIDER
ABOUT EGRIFTA SV TM.
FIND A SPECIALIST
AT EGRIFTASV.COM
Actual patient living with HIV.
IMPORTANT INFORMATION FOR PATIENTS ABOUT EGRIFTA SVTM (TESAMORELIN FOR INJECTION)
What is EGRIFTA SVTM (tesamorelin for injection)?
• EGRIFTA SVTM is an injectable prescription medicine
used to reduce excess abdominal fat in adult patients
living with HIV and lipodystrophy. EGRIFTA SVTM is a
growth hormone-releasing factor (GHRF) analog.
• EGRIFTA SVTM is not for weight loss management.
• The long-term safety of EGRIFTA SVTM on the heart
and blood vessels (cardiovascular) is not known.
• It is not known whether taking EGRIFTA SVTM helps
improve how well you take your antiretroviral
medications.
• It is not known if EGRIFTA SVTM is safe and effective
in children, do not use in children.
You should not take EGRIFTA SVTM if you:
• Have a pituitary gland tumor, surgery, or other problems
related to your pituitary gland, or have had radiation
treatment to your head or head injury.
• Have active cancer.
• Are allergic to tesamorelin or any of the ingredients
in EGRIFTA SVTM.
• Are pregnant or become pregnant. If you become
pregnant, stop using EGRIFTA SVTM and talk with your
healthcare provider.
• Are less than 18 years of age.
Before using EGRIFTA SVTM, tell your healthcare
provider if you:
• Have or have had cancer.
• Have problems with blood sugar or diabetes.
• Have scheduled heart or stomach surgery.
• Have breathing problems.
• Are breastfeeding or plan to breastfeed.
• Are taking any other prescription and non-prescription
medicines, vitamins, and herbal supplements.
EGRIFTA SVTM may cause serious side effects including:
• Increased risk of new cancer in HIV positive patients
or your cancer coming back (reactivation). Stop using
EGRIFTA SVTM if any cancer symptoms come back.
• Increased levels of your insulin-like growth factor-1
(IGF-1). Your healthcare provider will do blood tests
to check your IGF-1 levels while you are taking
EGRIFTA SVTM.
• Serious allergic reaction such as rash or hives
anywhere over the body or on the skin, swelling of the
face or throat, shortness of breath or trouble
breathing, fast heartbeat, feeling of faintness or
fainting, itching and reddening or flushing of the skin.
If you have any of these symptoms, stop using
EGRIFTA SVTM and get emergency medical help right
away.
• Swelling or fluid retention. Call your healthcare
provider if you have swelling, an increase in joint
pain, or pain or numbness in your hands or wrist.
• Increase in blood sugar (glucose) or diabetes.
• Injection site reactions. Injection site reactions
are a common side effect of EGRIFTA SVTM, but may
sometimes be serious.
• Increased risk of death in people who have critical
illness because of heart or stomach surgery, trauma
of serious breathing (respiratory) problems has
happened when taking certain growth hormones.
The most common side effects of EGRIFTA SVTM include:
• Pain in legs and arms
• Muscle pain
These are not all of the possible side effects of
EGRIFTA SVTM. For more information, ask your healthcare
provider or pharmacist. Call your doctor for medical
advice about side effects. You may report side effects to
FDA at 1-800-FDA-1088 or to THERA patient support®
toll-free at 1-833-23THERA (1-833-238-4372).
This information is not intended to replace discussions
with your doctor. For additional information about
EGRIFTA SVTM, go to: www.egriftasv.com for the full
Prescribing Information, Patient Information and
Patient Instructions for Use, and talk to your doctor.
For more information about EGRIFTA SVTM contact
THERA patient support® toll-free at 1-833-23THERA
(1-833-238-4372).
EGRIFTA SV is a trademark of Theratechnologies Inc.
THERA patient support is a registered trademark of Theratechnologies Inc.
© 2020 Theratechnologies Inc. All rights reserved.
789-01-04/20 – 8,75x11,5
GayCityNews.com | June 25- July 15, 2020 17
/www.egriftasv.com
/EGRIFTASV.COM
/www.egriftasv.com
/GayCityNews.com
